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Aberrant inflammation is an enabling characteristic of tumorigenesis. Thus, signaling cas-
cades that alter inflammatory activation and resolution are of specific relevance to disease
pathogenesis. Pattern recognition receptors (PRRs) are essential mediators of the host
immune response and have emerged as critical elements affecting multiple facets of tumor
pathobiology. The nucleotide-binding domain and leucine-rich repeat containing (NLR) pro-
teins are intracellular PRRs that sense microbial and non-microbial products. Members of
the NLR family can be divided into functional sub-groups based on their ability to either
positively or negatively regulate the host immune response. Recent studies have identi-
fied a novel sub-group of non-inflammasome forming NLRs that negatively regulate diverse
biological pathways associated with both inflammation and tumorigenesis. Understanding
the mechanisms underlying the function of these unique NLRs will assist in the rationale
design of future therapeutic strategies targeting a wide spectrum of inflammatory diseases
and cancer. Here, we will discuss recent findings associated with this novel NLR sub-group
and mechanisms by which these PRRs may function to alter cancer pathogenesis.
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INTRODUCTION
The intimate association between inflammation and cancer was
first noted over 150 years ago by Rudolf Vierchow (1, 2). Indeed
today, aberrant inflammation is considered both an emerging hall-
mark of tumorigenesis and an enabling characteristic of cancer
(3). Tumorigenesis is a multistep process and inflammation func-
tions at multiple levels to both antagonize and enhance tumor
initiation and progression (3). During the early stages of tumori-
genesis, an inflammatory microenvironment serves as an enabling
characteristic to activate diverse signaling pathways and drive the
progression of pre-malignant and malignant lesions toward can-
cer (3–5). In later stages, cancer cells typically acquire a diverse
repertoire of defense mechanisms that allow the cells to both pas-
sively and actively evade immune surveillance and elimination
(3, 6, 7). This immune system subversion is an emerging hall-
mark of cancer and serves to remove the most effective barriers
employed by the host to defend against neoplasia, late-stage tumor,
and micro-metastasis progression (3).
Pattern recognition receptors (PRRs) are an essential compo-
nent of the host immune system and significantly contribute to
cancer pathobiology. There are 4 major families of PRRs that
have been implicated in tumorigenesis, including the toll-like
receptors (TLRs), the nucleotide-binding domain and leucine-rich
repeat containing (NLR) family of sensors, C-type lectin receptors
(CLRs), and RIG-I-like receptors (RLRs) (8). These receptor fami-
lies function to initiate inflammatory signaling cascades following
the direct or indirect recognition of pathogens, damage and stress
through sensing highly conserved pathogen-associated molecu-
lar patterns (PAMPs), and damage-associated molecular patterns
(DAMPs). In addition to their roles in facilitating the immune
response, PRRs also play fundamental roles in the regulation of
proliferation, cell survival and death, reactive oxygen species gen-
eration, angiogenesis, and tissue remodeling and repair (8). In
the context of cancer, PRRs drive the immune response follow-
ing exposure to potentially carcinogenic pathogens,environmental
exposures to mutagenic agents and insults, and cancer-associated
cellular damage and stress (9–16). In general, increased PRR sig-
naling creates an enriched, pro-inflammatory microenvironment
that is favorable for tumor initiation and progression (17). Thus,
we find that PRRs are stuck in a “Goldilocks Conundrum.” Robust
PRR activation is critical in driving the host immune response
following PAMP and DAMP exposure; whereas, an overzealous
and persistent immune response driven by PRR activation can
cause significant collateral damage to the host tissue that ultimately
results in chronic inflammation and cancer.
To date, the majority of studies evaluating PRR signaling in
cancer have focused on members of the TLR family. However,
new and emerging findings have revealed a significant role for
members of the NLR family in contributing either directly or indi-
rectly to a variety of hallmarks associated with cancer, including
inflammation, cell death, tumor growth, angiogenesis, invasion,
and metastasis (18–26). There are at least 23 distinct NLR and
NLR-like proteins that have been identified in humans and 34
family members identified in mice (23, 27–29). The NLR pro-
teins function as cytosolic receptors and sensors to detect intra-
cellular PAMPs and DAMPs. Since their discovery, a variety of
names have been used to describe the members of this gene
family and their respective proteins. For example, these PRRs
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have been previously referred to as CATERPILLERs, NOD-like
receptors, NACHT-leucine-rich repeats (LRR), and NBD-LRR
proteins (28). This resulted in a lack of consistency in the field
and resulted in the currently accepted and standardized nomen-
clature defining the NLRs as the NLR gene family (28). These
proteins contain a highly conserved tripartite domain structure
(28). The N-terminal domain of the protein is comprised of a
variable, but limited number of effector domains that can include
combinations of acidic transactivation domains (NLRA proteins),
baculoviral inhibitory repeat (BIR)-like domains (NLRB pro-
teins), caspase recruitment domains (NLRC proteins), and pyrin
domains (NLRP proteins) (28). These N-terminal domains func-
tion to recruit adaptor, intermediary, or effector molecules that
drive downstream signaling. The core of the protein is com-
prised of a conserved NACHT nucleotide-binding domain, which
facilitates oligomerization (28). The C-terminal domain of the
protein contains multiple LRR elements, which are essential for
ligand sensing (28). Each LRR element is typically 28–29 residues
in length and each NLR may contain up to 33 individual LRR
elements (30, 31).
INFLAMMASOME FORMING NLRs IN CANCER
One of the most fundamental roles of the NLR family is to reg-
ulate pro-inflammatory cytokines and chemokines that drive the
host innate immune response to pathogens and environmental
insults. Key to this response is the proper regulation of IL-1β
and IL-18, which are both potent pro-inflammatory cytokines
that affect diverse aspects of health and disease (32–37). Both
of these cytokines are generated in an immature pro-form that
requires post-translational cleavage for activation. A functional
sub-group of NLRs has been identified as driving this process
through the formation of a multi-protein complex termed the
inflammasome (32, 35, 36). Upon activation, the NLR is thought
to undergo a conformational change that allows the recruitment
and binding of adaptor and effector proteins and inflamma-
some formation (35). The inflammasome is composed of an
NLR that recognizes a specific repertoire of PAMPs and DAMPs,
the adaptor protein ASC, and pro-Caspase-1 (32). These sub-
units continue to multiplex, ultimately resulting in the matu-
ration and activation of Caspase-1, which subsequently drives
the cleavage and activation of IL-1β and IL-18. These inflam-
masome forming NLRs are by far the best characterized and
most highly studied members of the NLR family. To date, at
least 6 NLR and NLR-like proteins have been strongly implicated
in inflammasome formation, including NLRP1, NLRP3, NLRP6,
NLRC4, NLRC5, and the PYHIN family member AIM2 (NLR-
like) (32–37). Inflammasome forming NLRs significantly regulate
the tumor microenvironment by modulating cytokine production.
For example, many of the inflammasome forming NLRs have been
shown to significantly attenuate inflammation and tumorigene-
sis in mouse models of colitis-associated colorectal cancer (CAC)
by regulating IL-18 production (18, 19, 21, 22, 38–40). In addi-
tion to being a potent pro-inflammatory cytokine, IL-18 is also
secreted by epithelial cells to stimulate regeneration and repair and
improve barrier function in the colon, thus loss of this cytokine
in NLR inflammasome deficient mice enhances tumorigenesis
(41). Beyond colon cancer, NLR inflammasome activation may
also play important roles in many other types of cancer, includ-
ing breast cancer, skin cancers, and virus-associated hepatocellular
carcinoma (25, 26, 42–47).
NON-INFLAMMASOME FORMING NLRs THAT NEGATIVELY
REGULATE INFLAMMATION
While the inflammasome forming NLRs are the best character-
ized members of this PRR family, recent studies have identified
a functional sub-group of NLRs that negatively regulate inflam-
mation (48–54). This sub-group is currently composed of three
NLR family members, NLRP12, NLRX1, and NLRC3 (Figure 1).
NLRP12 was one of the first NLR proteins to be described and
is the best characterized member of this functional NLR sub-
group. NLRP12 was previously known as monarch-1 and PYPAF7
and was originally suggested to form an inflammasome with ASC
in overexpression systems (55, 56). In these overexpression stud-
ies, transient transfection of NLRP12 and ASC was also shown
to induce the transcription of an NF-κB reporter construct (56).
Thus, these early in vitro studies initially suggested that NLRP12
was an inflammasome forming NLR and a positive regulator of
NF-κB signaling. These findings are also consistent with human
data that has identified mutations in NLRP12 linked to a spectrum
of hereditary periodic fever syndromes. The disorders associated
with NLRP12 mutations are characterized by redox alterations
and enhanced secretion of IL-1β, which are similar to the char-
acteristics associated with the family of diseases linked to gain-
of-function mutations in the NLRP3 gene (57–59). Interestingly,
these diseases are associated with increased caspase-1 activity, are
sensitive to therapeutics targeting IL-1β (anakinra), and appear to
be independent of NF-κB activation (57–59). However, the ability
of NLRP12 to form a functional inflammasome under physio-
logical situations and in the context of human disease appears to
occur only under highly specific conditions and is an area of cur-
rent investigation (60, 61). Indeed, several studies have evaluated
NLRP12 inflammasome formation ex vivo and using Nlrp12−/−
mice under a variety of conditions and have directly shown that
this NLR does not regulate IL-1β/IL-18 maturation (62–69). The
prevailing literature associated with NLRP12 indicates that this
protein functions as a negative regulator of inflammation by mod-
ulating canonical and non-canonical NF-κB signaling (48, 49, 62,
65, 66, 68, 70–73). NLRP12 negatively regulates non-canonical
NF-κB signaling through its association with TRAF3 and NF-κB
inducing kinase (NIK) (49, 68). This interaction leads to the degra-
dation of NIK and subsequent attenuation of p100 cleavage to p52
(Figure 1). Similarly, NLRP12 attenuates canonical NF-κB signal-
ing through the inhibition of IRAK-1 phosphorylation (48, 66, 71)
(Figure 1). In addition to directly mediating the NF-κB cascade,
NLRP12 has also been shown to attenuate ERK signaling, though
the exact mechanism has yet to be fully resolved (66, 68). Thus,
while some conflicting data has been reported, most issues can be
resolved by considering the technical limitations of the assays used
to define the respective mechanisms and the specific models being
evaluated.
NLRX1 was originally characterized in 2008, and was shown
to negatively regulate the host anti-viral immune response (51).
NLRX1 is unique among the NLRs due to its mitochondrial local-
ization and its relatively undefined N-terminal domain. Similar
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FIGURE 1 | Schematic illustrating NLR attenuation of canonical
and non-canonical NF-κB signaling. NF-κB is a master regulator of
gene transcription and contributes to several hallmarks of cancer.
NLRX1, NLRP12, and NLRC3 negatively regulate NF-κB signaling at
multiple levels. NLRX1 interacts with and inhibits TRAF6 and the IKK
complex resulting in the attenuation of NF-κB signaling following TLR
stimulation. Likewise, NLRC3 was also shown to interact with TRAF6
and attenuate NF-κB signaling through a similar mechanism. NLRP12,
has been shown to attenuate both the canonical NF-κB signaling
pathway through modulating the phosphorylation of IRAK-1 and the
non-canonical NF-κB pathway through interactions with TRAF3
and NIK.
to NLRP12, NLRX1 negatively regulates canonical NF-κB sig-
naling (50, 52) (Figure 1). NLRX1 associates with TRAF6 and
IκB kinase (IKK) through an activation signal-dependent mecha-
nism (50). Following stimulation, NLRX1 is rapidly ubiquitinated
and disassociates from TRAF6 to bind the IKK complex and
inhibit subsequent canonical NF-κB activation (50). In addition
to attenuating NF-κB signaling, NLRX1 also negatively regulates
type-I interferon (IFN-I) signaling through inhibiting the inter-
action between the PRR Rig-I and the mitochondrial anti-viral
signaling (MAVS) protein following virus exposure (50–52, 74,
75) (Figure 2). NLRX1 also functions as a positive regulator of
autophagy following virus exposure through interacting with the
protein TUFM and the mitochondrial immune signaling com-
plex (MISC), which also includes ATG5, ATG12, and ATG16L1
(74, 75) (Figure 2). Interestingly, autophagy also functions as a
negative regulator of IFN-I signaling and provides an additional
route for the negative regulatory properties of NLRX1. In addi-
tion to regulating NF-κB and IFN-I signaling, subsequent studies
have also shown that NLRX1 functions as a positive regulator of
ROS production in epithelial cells following Chlamydia trachoma-
tis infection, likely through interactions with the UQCRC2 protein
(76, 77) (Figure 2). Thus, it is clear that NLRX1 regulation is quite
complex and appears to occur through cell type, temporal and
signal-dependent mechanisms.
NLRC3 is the most recently characterized member of this
functional sub-group and has been shown to negatively regulate
NF-κB and IFN-I signaling (54, 78). NLRC3 was originally iden-
tified as a negative regulator of T cell function, in part through
delaying the degradation of IκBα (78). Subsequent studies have
since revealed that NLRC3 attenuates TLR signaling through
interacting with and modulating TRAF6 activity and inhibiting
canonical NF-κB signaling (54). NLRC3 has also been recently
shown to fine tune the host innate immune response to intracel-
lular DNA, DNA viruses, and c-di-GMP (53). NLRC3 impedes
STING-TANK-binding kinase 1 (TBK1) interactions and inhibits
STING trafficking, which results in an attenuation of subsequent
downstream activation of IFN-I genes (53).
While NLRP12, NLRX1, and NLRC3 each influence a vari-
ety of signaling pathways, the convergence on NF-κB signaling
appears to be a common strategy among the NLRs in this func-
tional sub-group to attenuate inflammation (Figure 1). Additional
mechanistic studies have revealed prevalent NLR–TRAF inter-
actions in these models and support the emerging hypothesis
that these NLRs function to inhibit NF-κB signaling through the
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FIGURE 2 | Schematic illustrating NLRX1 regulation of type-I interferon,
ROS and autophagy signaling. NLRX1 is localized to the mitochondria,
where it has been shown to bind with MAVS and prevent the interaction
between MAVS and RIG-I during the host anti-viral response. This interaction
significantly attenuates MAVS activation of IRF3 and IRF7 and results in
reduced IFN and IL-6 signaling. NLRX1 has also been shown to function as a
positive regulator of autophagy through its interactions with the mitochondrial
protein TUFM, and the mitochondrial immune signaling complex (MISC),
which includes Atg5–Atg12 and ATG16L1. This complex has been shown to be
important in promoting virus-induced autophagy and concurrently attenuating
IFN signaling. In addition to its role in attenuating host anti-viral signaling,
NLRX1 has also been shown to significantly augment ROS generation from
the mitochondria through interactions with UQCRC2 following infection with
specific species of bacteria.
formation of a multi-protein“TRAFasome”complex (54). Dysreg-
ulated NF-κB signaling and the additional pathways modulated
by these NLRs are critical features in cancer initiation and pro-
gression. Thus, the NLRs that modulate these signaling cascades
are highly relevant to cancer pathobiology and additional mech-
anistic insight will be critical for developing future therapeutic
strategies.
NEGATIVE REGULATORY NLRs IN CANCER PATHOBIOLOGY
While several studies have characterized the contribution of the
NLRP3, NLRC4, and NLRP6 inflammasomes in tumorigene-
sis, significantly less is known regarding the role of NLRs that
negatively regulate inflammation. Initial studies have focused
on NLRP12. In the context of cancer, somatic mutations in
human NLRP12 have been detected in several large scale screen-
ing studies evaluating a variety of cancer sub-types, includ-
ing glioblastoma, breast cancer, lung squamous cell carcinoma,
melanoma, prostate adenocarcinoma, and colon adenocarcinoma
(http://cancergenome.nih.gov/). However, broader linkage with
specific populations, causation, and mechanism for each mutation
has not yet been established. In mice, NLRP12 has been shown to
attenuate colorectal cancer. Using the AOM/DSS model of CAC,
Nlrp12−/− mice were shown to develop increased inflammation
and tumorigenesis (66, 68). Colon histopathology revealed signif-
icant epithelial cell damage and loss of barrier integrity in these
animals, which resulted in increased pro-inflammatory cytokine
and chemokine production (66, 68). These animals eventually
develop extensive pre-cancerous lesions, which result in signifi-
cantly increased areas of hyperplasia, dysplasia, and adenocarci-
noma (66, 68). These studies revealed that NLRP12 attenuates
inflammation and tumorigenesis through negatively regulating
NF-κB and ERK signaling (66, 68).
While the overall results of each study are quite complemen-
tary, it should be noted that a few mechanistic differences were
proposed. In one study, the increased tumorigenesis was attributed
to an increase in canonical NF-κB signaling (66). NF-κB signaling
was evaluated in vivo and in macrophages isolated from wild type
and Nlrp12−/− mice following PAMP stimulation and a signifi-
cant increase in the levels of p-p105, Rel-A, and p65 activity was
observed (66). Furthermore, loss of NLRP12 was shown to signif-
icantly increase the transcription of a variety of pro-inflammatory
mediators associated with canonical NF-κB signaling and colon
tumorigenesis, including Il-6,Tnf-α, and Cox2 (66). These findings
are consistent with earlier in vitro studies,which demonstrated that
NLRP12 functions as an antagonist of TLR and TNFR-induced
pro-inflammatory signals, in part through inhibiting IRAK-1
hyper-phosphorylation (48). In the second study, NLRP12 was
shown to attenuate colon tumorigenesis through negatively reg-
ulating non-canonical NF-κB signaling. While some markers of
canonical NF-κB signaling were found to be transiently increased
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in the absence of NLRP12, this study revealed a significant increase
in NIK activation and p100 to p52 cleavage in primary cells and
in colon tissues isolated from Nlrp12−/− mice during disease
progression (68). These data are highly consistent with previous
in vitro studies associating NLRP12 activity with NIK suppres-
sion and attenuation of non-canonical NF-κB signaling (49, 79).
Loss of NLRP12 resulted in a significant increase in Cxcl12 and
Cxcl13 expression in the colons from Nlrp12−/− mice (68). These
chemokines are highly associated with non-canonical NF-κB acti-
vation and cancer (49, 68, 80–82). CXCL12 (SDF-1) and CXCL13
(BLC) and their respective receptors CXCR4 and CXCR5 have
been implicated in tumor growth, metastasis, and are critical for
the regulation of the tumor microenvironment in multiple can-
cer sub-types as a component of the tumor “Immunome” (3,
83–85). Regulation of the NF-κB signaling pathway is highly com-
plex. The apparent discrepancies between these two studies can be
reconciled by previous findings, which show that non-canonical
NF-κB signaling can influence both the canonical pathway and
MAPK signaling (86, 87). It is also highly likely that NLRP12
regulates canonical and non-canonical NF-κB signaling through
currently undefined cell type, temporal and/or stimuli-specific
mechanisms.
To date, neither NLRX1 nor NLRC3 have been directly eval-
uated in the context of cancer. As previously stated, both of
these NLRs negatively regulate NF-κB signaling and would be
expected to attenuate tumorigenesis through mechanisms similar
to those described for NLRP12. However, each also regulates path-
ways other than NF-κB that could dramatically influence cancer
pathobiology. For example, NLRX1 has been shown to addition-
ally regulate ROS production and autophagy. The dysregulation
of oxidative stress signaling is a well-established and impor-
tant element of tumor development (88). Similarly, autophagy
is thought to have a dual function in cancer, where it can attenuate
tumor initiation by suppressing tissue damage and inflamma-
tion signaling or it can function as a tumor promoter to sustain
metabolism, growth, and survival through metabolite recycling
(89, 90). Thus, it is highly likely that NLRX1 will contribute to
tumorigenesis; however, it is difficult to speculate which of its
many biologic functions will have a greater influence on disease
pathogenesis.
CONCLUSION
The recent characterization of this unique sub-group of NLRs that
function to attenuate inflammation emphasizes the point that a
significant number of the identified NLR proteins in humans have
yet to be adequately characterized. Identifying the unique reg-
ulatory and signaling pathways modulated by these NLRs is an
essential step toward ultimately developing effective therapeutics
targeting these proteins and the pathways they modulate. Char-
acterizing unidentified ligands, cell type and temporal regulatory
mechanisms, and redundant functions of these NLR family mem-
bers will significantly improve our understanding of the contribu-
tion of these proteins in maintaining immune system homeostasis.
It is also clear that NLRs significantly impact cancer pathobiology,
beyond colorectal cancer. Additional studies are necessary to better
define the contribution of both inflammasome forming NLRs and
non-inflammasome forming NLRs in modulating the hallmarks
of cancer.
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